Revenue Growth - Revenue increased by 49% to $42.0 million for the three months ended December 31, 2021, compared to $28.2 million for the same period in 2020[120]. - Synthetic gene revenue grew to $13.5 million, up from $9.7 million in the previous quarter, driven by an increase in the customer base and new product launches[106]. - Antibody discovery revenue rose to $4.8 million from $2.6 million in the previous quarter, attributed to growth from the recent Abveris acquisition[106]. - The Americas accounted for 54% of total revenues, while EMEA and APAC contributed 37% and 9%, respectively[116]. Expenses and Losses - Net loss attributable to common stockholders was $45.6 million for the three months ended December 31, 2021, compared to a net loss of $32.9 million for the same period in 2020[112]. - Research and development expenses increased by 62% to $22.6 million, up from $14.0 million in the same quarter of 2020, primarily due to increased headcount and outside services[122]. - Selling, general and administrative expenses increased to $51.1 million from $35.8 million in the previous quarter, driven by higher payroll and professional services costs[106]. - Selling, general and administrative expenses increased to $51.1 million in Q4 2021 from $28.8 million in Q4 2020, a 77% increase, primarily due to payroll expenses rising by $15.6 million[123]. Cash Flow and Investments - Net cash used in operating activities was $(46.7) million in Q4 2021, compared to $(24.9) million in Q4 2020, reflecting a worsening cash flow situation[139][140]. - Investing activities in Q4 2021 resulted in a net cash outflow of $(226.6) million, significantly higher than $(45.9) million in Q4 2020, indicating increased investment activity[141][142]. - Financing activities led to a net cash outflow of $(1.0) million in Q4 2021, contrasting sharply with a net inflow of $326.9 million in Q4 2020, highlighting a shift in financing strategy[143][144]. - As of December 31, 2021, the company had $191.6 million in cash and cash equivalents, $110.2 million in short-term investments, and $106.8 million in long-term investments, indicating a strong liquidity position[129]. - The company had $69.7 million in commitments for capital expenditures as of December 31, 2021, reflecting ongoing investment in growth initiatives[137]. Operational Expansion - The company shipped approximately 125,000 genes in the three months ended December 31, 2021, a 49% increase from approximately 84,000 genes in the same period of 2020[120]. - The company has expanded its manufacturing operations with a 12-year lease for approximately 111,000 square feet and an additional 101,000 square feet in the Portland area[109]. - The company entered into a 7-year operating lease for office space in South San Francisco, with total future minimum lease payments of $13.1 million, indicating expansion plans[148]. Tax and Interest - The income tax benefit recorded in Q4 2021 was $10.4 million, a significant increase from an expense of $(0.05) million in Q4 2020, representing a 227% change[126]. - Interest income rose to $0.2 million in Q4 2021, a 15% increase from $0.1 million in Q4 2020, while interest expense decreased by 78% to $(0.03) million[125]. Financial Position and Risks - The company had cash, cash equivalents, and marketable securities totaling $408.7 million as of December 31, 2021, down from $477.9 million as of September 30, 2021[164]. - The company is exposed to interest rate risk, with a hypothetical 10% relative change in interest rates not expected to materially impact financial statements[165]. - Foreign currency transactions primarily involve the Euro, Chinese Yuan, and British Pound, exposing the company to foreign exchange risk[166]. - The company does not use derivative financial instruments for speculative trading purposes, minimizing counterparty risk through creditworthy banks[167]. Goodwill and Intangible Assets - Goodwill is tested for impairment annually, with significant judgment required to assess fair value against carrying value[162]. - Intangible assets from business acquisitions include goodwill and development technology, with critical estimates based on projected revenues and discount rates[160]. Revenue Recognition - Biopharma revenue primarily consists of research and development agreements, with contract assets of $4.4 million and contract liabilities of $0.9 million as of December 31, 2021[157]. - Revenue is recognized based on the timing of development activities, with no revenue recognized from performance obligations satisfied in previous periods[157]. - The company recognizes revenue from functional license agreements when the license is transferred to the customer, allowing them to use and benefit from the license[156]. Stock-Based Compensation - Stock-based compensation includes performance-based stock units (PSUs) granted to executive officers and senior employees, with fair value calculated using the Black-Scholes method[159].

Financial Data and Key Metrics Changes - The company reported record revenue of $42 million for Q1 2022, representing a sequential growth of 11% and a year-over-year growth of 49% [39] - Orders for the quarter were $49.6 million, a sequential increase of 10% and a year-over-year growth of 48% [39] - Gross margin for Q1 was 35.6%, slightly up from 35.5% in Q1 2021 [49] - The company ended the quarter with cash and investments of approximately $409 million [40] Business Line Data and Key Metrics Changes - SynBio revenue reached $18 million, up from $13.9 million in the same quarter of fiscal 2021, with orders at $22.2 million, a 40% increase year-over-year [46][43] - NGS revenue was $19.2 million, reflecting a 23% growth year-over-year, with orders at $21.8 million, a 28% increase year-over-year [45][41] - Biopharma revenue was approximately $4.8 million, including one month of contribution from the Abveris acquisition [46] Market Data and Key Metrics Changes - Healthcare revenue was $21 million, up from $16 million in Q1 2021; Industrial Chemicals revenue was $12.5 million, compared to $7.1 million in the same period [47] - EMEA region revenue was $15.4 million, significantly up from $9.1 million in Q1 2021, while APAC revenue reached $4 million, up from $1.8 million [48] Company Strategy and Development Direction - The company plans to continue expanding its customer base in synthetic biology and aims to bring the Factory of the Future online to reduce turnaround times and launch new products [61] - In NGS, the focus is on growing the market for liquid biopsy and MRD, with expectations of significant revenue expansion as these products reach commercialization [62] - The biopharma segment aims to leverage the integration of Abveris to enhance revenue through partnerships and internal pipeline advancements [63] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth opportunities in NGS, particularly in liquid biopsy and MRD, despite short-term impacts from the Omicron variant [39][86] - The company anticipates a strong second half of fiscal 2022, driven by increased customer adoption and product launches [86] Other Important Information - The company has increased its revenue guidance for fiscal 2022 to a range of $189 million to $198 million, up from the previous guidance of $183 million to $193 million [54] - The gross margin guidance remains at 35% to 37%, reflecting ongoing costs associated with the Portland brand [56] Q&A Session Summary Question: Can you discuss the path forward for the Enzymatic Synthesis platform? - The company plans to develop its own hardware for Enzymatic Synthesis, particularly for enterprise data storage, while remaining open to partnerships for other markets [67][69] Question: What is the pricing variation for NGS products, especially for liquid biopsy? - Pricing varies based on the number of probes in a panel and the volume of samples ordered, with the company targeting to capture 5% to 10% of the liquid biopsy market [70][71] Question: What drove the strong growth in the EMEA region, and is it sustainable? - Growth in EMEA is attributed to investments in the commercial organization and strong demand across key countries, with expectations for continued growth [75] Question: Were the production challenges from the last quarter resolved? - Production issues were resolved, and the company shipped a record 125,000 genes, indicating strong demand in SynBio [82] Question: Why is the NGS guidance flat despite strong momentum? - The flat guidance reflects near-term conservatism, but the company expects significant growth in the second half of the year driven by customer adoption [86] Question: How has the nature of conversations in biopharma changed? - The company has gained a strong reputation, making it easier to engage with larger, more conservative companies compared to a few years ago [101]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38720 Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 46-205888 (Sta ...

l - W ● BIOSCIENCE . Fiscal 2021 4Q and Year-End Financial Results November 22, 2021 Agenda | --- | --- | --- | |----------------------------------------|-------|-------| | | | | | | | | | Welcome Angela Bitting | | | | SVP, Corporate Affairs | | | | Quarterly and Annual Highlights | | | | Emily Leproust | | | | Chief Executive Officer | | | | Financial and Operational Performance | | | | Jim Thorburn | | | | Chief Financial Officer | | | | Pipeline & Milestones | | | | Emily Leproust Chief Executive Office ...

| W ● BIOSCIENCE . ● Fiscal 2021 3Q Financial Results August 6, 2021 Agenda | --- | --- | --- | |----------------------------------------|-------|-------| | | | | | | | | | Welcome Angela Bitting | | | | SVP, Corporate Affairs | | | | Quarterly Highlights | | | | Emily Leproust | | | | Chief Executive Officer | | | | Financial and Operational Performance | | | | Jim Thorburn | | | | Chief Financial Officer | | | | Pipeline & Milestones | | | | Emily Leproust Chief Executive Officer | | | Q&A Session 2 | TWI ...

Table of Contents FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Mark One) Washington, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38720 Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 46-2058888 ...

Twist Bioscience Corp. (NASDAQ:TWST) Q3 2021 Earnings Conference Call August 6, 2021 8:00 AM ET Company Participants Emily Leproust – CEO and Co-Founder Angela Bitting – SVP of Corporate Affairs Jim Thorburn – CFO Conference Call Participants Doug Schenkel – Cowen Matt Sykes – Goldman Sachs Catherine Schulte – Baird Vijay Kumar – Evercore ISI Matt Larew – William Blair (ph) Tycho Peterson – JP Morgan Operator Welcome to Twist Biosciences, Fiscal 2021, Third Quarter Financial results conference call. At this ...

Financial Data and Key Metrics Changes - Revenue for Q2 2021 was $31.2 million, representing a 62% increase year-over-year and an 11% sequential increase [9][37] - Orders totaled $41.7 million, a 69% increase year-over-year and a 24% sequential increase [10][37] - Gross margin for the quarter was 39%, up from 30% in the same quarter last year [38][51] Business Line Data and Key Metrics Changes - Synthetic Biology (synbio) revenue was $12.9 million, with orders exceeding $20 million for the quarter [10][41] - Next-Generation Sequencing (NGS) revenue reached $17 million, a 120% year-over-year increase [44] - Biopharma revenue was $1.3 million, reflecting only a portion of the upfront fees from partnerships [27][47] - Data Storage engineering progress was made towards achieving $100 per terabyte [32][93] Market Data and Key Metrics Changes - Americas revenue was $18.6 million, up from $12.1 million year-over-year [48] - EMEA revenue was $10 million, compared to $6.2 million in the same period last year [48] - APAC revenue increased to $2.7 million from $0.9 million, indicating a strong rebound in Asia [49] Company Strategy and Development Direction - The company is focusing on expanding its customer base and product mix in synthetic biology [11][12] - Plans to operationalize the "Factory of the Future" in Portland by 2022 to support growth [13][14] - The competitive landscape is being monitored, particularly regarding enzymatic synthesis technologies [15][16] Management's Comments on Operating Environment and Future Outlook - Management noted strong revenue growth and order trends across all business segments despite the ongoing pandemic [8][9] - The company is optimistic about continued growth in NGS and synbio, with expectations for further diversification of revenue streams [63] - There are concerns regarding supply chain headwinds, but these have been factored into the financial guidance [56][89] Other Important Information - The company has increased its fiscal year 2021 revenue guidance from $110 million to a range of $121 million to $129 million [57] - The gross margin guidance for the year has been raised to 36% to 38% [58] - The company ended the quarter with approximately $555 million in cash and short-term investments [38][55] Q&A Session Summary Question: Competitive landscape regarding distributed models for oligos and gene synthesis - Management indicated that the distributed model is currently not competitive due to quality differences, with their offerings being superior [68][69] Question: Increase in gross margin guidance - The increase is attributed to a higher share of NGS products and leveraging fixed costs [71] Question: Academic customer trends and geographic dynamics - Academic sector orders improved significantly, particularly in Asia and Europe, indicating a strong recovery [73][74] Question: Biopharma partnership expectations and development timelines - The biopharma funnel is strong, with ongoing partnerships and programs, although timelines are dependent on partners [79][103] Question: Academic market rebound and its impact on NGS - Academic orders increased by approximately 20%, which positions the company well for the second half of the year [81][82] Question: Supply headwinds and guidance - Supply chain issues are included in the guidance, and the company is actively working to resolve them [88][89] Question: Data storage milestones and cost metrics - The company is progressing towards its goal of $100 per terabit, having achieved significant engineering milestones [93][96]

l W ● BIOSCIENCE . Fiscal 2021 2Q Financial Results May 6, 2021 Agenda | --- | --- | --- | --- | --- | |---------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | Welcome | | | | | | | | | | | | Jim Thorburn Chief Financial Officer | | | | | | Quarterly Highlights | | | | | | Emily Leproust | | | | | | Chief Executive Officer | | | | | | Financial and Operational Performance | | | | | | Jim Thorburn | | | | | | Chief Financial Officer | | | | | | Pipeline & Milestones ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38720 Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 46-2058888 ...